Cargando…
SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3
BACKGROUND: It remains unclear whether assessing programmed death-ligand 1 (PD-L1) expression by SP142 plus 22C3 adds value for predicting the response to immunotherapy in non-small cell lung cancer (NSCLC). METHODS: This retrospective multicenter study included patients with advanced NSCLC treated...
Autores principales: | Nakahama, Kenji, Osawa, Masahiko, Izumi, Motohiro, Yoshimoto, Naoki, Sugimoto, Akira, Nagamine, Hiroaki, Ogawa, Koichi, Matsumoto, Yoshiya, Sawa, Kenji, Tani, Yoko, Kaneda, Hiroyasu, Mitsuoka, Shigeki, Watanabe, Tetsuya, Asai, Kazuhisa, Kawaguchi, Tomoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830255/ https://www.ncbi.nlm.nih.gov/pubmed/36636414 http://dx.doi.org/10.21037/tlcr-22-496 |
Ejemplares similares
-
Association of thyroid transcription factor‐1 with the efficacy of immune‐checkpoint inhibitors in patients with advanced lung adenocarcinoma
por: Nakahama, Kenji, et al.
Publicado: (2022) -
Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non–small cell lung cancer
por: Nakahama, Kenji, et al.
Publicado: (2022) -
Differences in molecular epidemiology of lung cancer among ethnicities (Asian vs. Caucasian)
por: Izumi, Motohiro, et al.
Publicado: (2020) -
Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis
por: Nakahama, Kenji, et al.
Publicado: (2022) -
Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors
por: Izumi, Motohiro, et al.
Publicado: (2021)